US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ドイツ
TG
DBV Technologies (DBV) 銘柄情報

DBV Technologies (DBV)

2.878

0.134

(4.88%)

終了 6月12日 5:00AM

DBV Technologies (DBV) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

2.878

( 4.88% )

買値

2.85

売値

2.906

出来高

507

2.776 日の範囲 2.834

1.46 52 週間の範囲 5.00

時価総額

前日終値

2.744

始値

2.776

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

1,044,279 €

発行済株式数

295,914,379

配当利回り

PER

-4.35

1 株当たり利益 (EPS)

-0.76

歳入

5.74M

純利益

-167.45M

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanu... DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.dbv-technologies.com

本社

Châtillon, France

設立

2026

DBV Technologies is listed in the Healthcare sector of the Tradegate (DE) with ticker DBV. The last closing price for DBV Technologies was 2.74 €. Over the last year, DBV Technologies shares have traded in a share price range of 1.46 € to 5.00 €.

DBV Technologies currently has 295,914,379 shares in issue. The market capitalisation of DBV Technologies is 851.64 € million. DBV Technologies has a price to earnings ratio (PE ratio) of -4.35.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.178	-5.82460732984	3.056	3.056	2.66	6349	2.88000334	DE
4	-0.584	-16.8688619295	3.462	3.462	2.66	3305	3.04455145	DE
12	-0.402	-12.256097561	3.28	3.892	2.66	5087	3.47793096	DE
26	-0.542	-15.8479532164	3.42	5	2.66	7958	3.56404823	DE
52	1.32	84.7240051348	1.558	5	1.46	9330	2.96518641	DE
156	-0.062	-2.10884353741	2.94	5	0.52	6586	2.32770612	DE
260	-0.062	-2.10884353741	2.94	5	0.52	6586	2.32770612	DE

DBV - Frequently Asked Questions (FAQ)

What is the current DBV Technologies share price?

The current share price of DBV Technologies is 2.878 €

How many DBV Technologies shares are in issue?

DBV Technologies has 295,914,379 shares in issue

What is the market cap of DBV Technologies?

The market capitalisation of DBV Technologies is EUR 851.64M

What is the 1 year trading range for DBV Technologies share price?

DBV Technologies has traded in the range of 1.46 € to 5.00 € during the past year

What is the PE ratio of DBV Technologies?

The price to earnings ratio of DBV Technologies is -4.35

What is the cash to sales ratio of DBV Technologies?

The cash to sales ratio of DBV Technologies is 169.9

What is the registered address of DBV Technologies?

The registered address for DBV Technologies is BAtiment IRO, Châtillon, Ile-de-France, 92320

What is the DBV Technologies website address?

The website address for DBV Technologies is www.dbv-technologies.com

Which industry sector does DBV Technologies operate in?

DBV Technologies operates in the Biotechnology & Life Sciences sector

JohnnyRotton

JohnnyRotton 5分前

Wasn't to get sellers cause no one bought my sell order, cant get out now. Stuck. Just a small order.

jimr1717

jimr1717 5分前

I seriously doubt Nelson or Hawkins care who there marks are that they dump their shares on

ElectricDwarf15

ElectricDwarf15 8分前

Stuck short INHD after the T12 halt and looking to connect with anyone holding long shares who wants to exit.

I'm with Cobra DM me if interested.

knrorrel

knrorrel 9分前

$PAVD - It kicks off today. You might think—after the stock was bought up at a really nice, low price yesterday—that we’re going to skyrocket today, and all the people who didn't have the guts to buy yesterday and have been waiting on the sidelines will jump in; the stock could become a multi-dolla

ap17

Word on the street, the village Idiot, aka sims is going to change the traffic pattern. LMFAO
Don't forget! This about YOU! OUCH!!!
Might want to change that traffic pattern....so you can sit! LMFAO!!

https://www.instagram.com/p/DSS1QQ4EZk9/

Elon Musk: congratulations! Our country is lucky to have you…and you have excelled through hard work to help create the modern world more than anyone since Steve Jobs. You also are a father of many kids and are active in their lives. You have a great sense of humor and wit, and never before in histo

ace65

Up 100% ...excellent day with massive volume.
No complaints here.
Bought a chunk at .0004 and added .0005s.
Looking like .00s are coming.

knrorrel

knrorrel 14分前

It kicks off today. You might think—after the stock was bought up at a really nice, low price yesterday—that we’re going to skyrocket today, and all the people who didn't have the guts to buy yesterday and have been waiting on the sidelines will jump in; the stock could become a multi-dollar runner—

jour_trader

jour_trader 15分前

Valid question. Elite was up against a billion dollar organization known for dragging out patent protections time and time again. I think Elite and Accord’s cases brought to light the craziness of what Purdue was doing and perhaps the cases prevented further attempts at extending patents that the co

knrorrel

knrorrel 18分前

GM - watch $PAVS today, bid / ask moving higher 🚀

ddls

You know the stock is in trouble when even ddls's posts start thinning out.

Everyone's waiting for financials next year to see if any progress is being made here. Until then we should call BioElectronics Boring BIEL.

jour_trader

jour_trader 20分前

Yes, precisely. Now they can include with more certainty the financial value of Oxy in the DCF.

jour_trader

jour_trader 22分前

Nasrat will likely now be able to provide more clarification with case officially ending. Been a long road with a decent outcome. Eager to watch Accord to see what takes place with them and if they have first to file rights.

mrwrn2010

mrwrn2010 22分前

Saw that too. Possible M&A clause? 👀🧐🤔

ace65

WOW...just saw the eod Level II .WTF happened.
A high of .0037 million bought.

mrwrn2010

mrwrn2010 23分前

Even more reason to transfer full Adderall rights to Elite now. Methadone and Ropinirole alone ain’t gonna get us anywhere near the growth we need in the near term.

jour_trader

jour_trader 24分前

Also, #3 - should Elite sell or transfer ANDA…

mrwrn2010

mrwrn2010 25分前

It seems like Elite can amend the existing filing from a P IV to a P III if I’m reading the document correctly. So still, doesn’t make sense. Let us get the approval whenever and we’ll wait to launch as soon as those patents are up (assuming no one else has exclusivity).

Just give me $1.50

Just give me $1.50 27分前

Elite's attorneys are regarded, just like it's CEO.

We ain't launching Oxy until late 2028..........AT BEST.

jour_trader

jour_trader 28分前

I read that as submission to the FDA as in it buys Purdue even more time beyond the patent expiration date.

Lord Andreti

Lord Andreti 29分前

It’s far from going to no bid. Bid is high AF right now and not something you see daily around the OTC market.

Something is brewing and this is for sure going places (bid still gives the biggest tells)…I just don’t think it’s going be that big of a deal, anymore, after this crap.

OMOLIVES

OMOLIVES 30分前

Also, look at the past six Months. They had 7.5 - 1 Billion volume days over the past six Months. Backlog, bottleneck....fucked.

Just give me $1.50

Just give me $1.50 33分前

Does this mean every penny spent on this case was a complete waste of time since we can't launch until the patents are up?

Or in other words, we got absolutely nothing out of it, except losing money on attorney fees?

So Elite failed?

Thanks.

along4zride

along4zride 33分前

BIG IPO TOMORROW. Real company on major exchange. Excitement enthusiasm, whole world watching. Will be setting a benchmark for all going forward. Not some pink sheet (FNMA) wanna be has been in conservatorship with total profit sweep waiting for a hand out . Most can recognize the difference. I am

DBV Technologies

FRCF33 - 01/2033

Graniteshares Faang Etp

Adamera Minerals (PK)

3.18% Inst 03apr2028

ARK Innovation ETF

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。